# The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020, Paragraph 181

Extent: E+W+S+N.I.

In regulation 222 (amendment of regulation 331 (findings and reports of inspections))—
(a) for paragraph (2) substitute—
“(2) In paragraph (1)—
(a) for “marketing authorisation” substitute “ UK marketing authorisation, EU marketing authorisation ”;
(b) in sub-paragraph (c), at the beginning, insert “ in the case of a product authorised under a UKMA(NI) or UKMA(UK), ”.”;
(b) for paragraph (3) substitute—
“(3) In paragraph (4)—
(a) for sub-paragraph (b) substitute—
“(b) the guidelines on good distribution practice—
(i) in the case of Great Britain, published under, or that apply by virtue of, regulation C17;
(ii) in the case of Northern Ireland, published by the European Commission in accordance with Article 84 of the 2001 Directive;”;
(b) after sub-paragraph (c) insert—
“(d) Schedule 12A; and
(e) the Implementing Regulation (as defined in regulation 177(5)).”.”.

---
Source: https://www.legislation.gov.uk/uksi/2020/1488/schedule/2/paragraph/181 (the official version)
Page: https://openlegislation.uk/human-medicines-amendment-etc-eu-exit-regulations-2020/schedule-2/paragraph-181
Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives.